Medi-Cal Just Cut GLP-1 Coverage for Weight Loss — What California Patients Need to Do Now

If you are a Medi-Cal member in California who has been using semaglutide or tirzepatide for weight loss, you may have already noticed: the coverage is gone.

Effective January 1, 2026, California’s Medicaid program stopped covering GLP-1 receptor agonists when prescribed for weight loss or weight-related indications in adults 21 and older. The California Medical Association confirmed the policy change and urged physicians to notify affected patients immediately.

The decision affects hundreds of thousands of Californians who were relying on Medi-Cal to access Ozempic, Wegovy, Mounjaro, and Zepbound for obesity treatment. For many, this means their prescription costs went from $0 to $900–$1,350 per month overnight.

What Changed and Why

GLP-1 medications remain covered by Medi-Cal when prescribed for type 2 diabetes with a documented diagnosis. The coverage cut applies specifically to weight loss as the primary indication. If your prescription was written for obesity management without a diabetes diagnosis, you are no longer covered.

The change is partly budget-driven. GLP-1 drugs are expensive, and as prescribing volumes have surged — fills increased more than 400% between 2021 and 2023 — state Medicaid programs have been under pressure to manage costs. California is not alone: several other states are reviewing or restricting GLP-1 obesity coverage.

Physicians treating Medi-Cal patients are now navigating a difficult situation. Many patients who had finally achieved meaningful weight loss are facing forced discontinuation — which research shows leads to regain of about 1.8 pounds per month for those on semaglutide and tirzepatide.

What This Means If You Have Diabetes

If you have a documented type 2 diabetes diagnosis, your coverage should not have changed. GLP-1s remain on Medi-Cal’s formulary for metabolic indications. Talk to your prescribing physician about ensuring your records reflect the full scope of your diagnosis.

If your diabetes risk is elevated but you do not yet have a formal diagnosis, ask your doctor about getting a hemoglobin A1C test. An A1C of 6.5% or above meets the diagnostic threshold.

Affordable Options That Do Not Require Medi-Cal

For Californians now paying out of pocket, the landscape has shifted in the past few months in ways that make access more realistic than it was two years ago.

1. TrumpRx (Government Discount Platform)

The Trump administration launched TrumpRx in early 2026, a government drug discount platform that partnered with Novo Nordisk and Eli Lilly to dramatically cut GLP-1 prices. Ozempic and Wegovy dropped to approximately $350 per month; Zepbound fell to $346 per month for cash-paying patients. TrumpRx does not sell medications directly but connects patients to participating pharmacies.

2. Telehealth Providers With Physician Oversight

Several licensed telehealth providers offer GLP-1 programs with full physician supervision at prices significantly below retail pharmacy costs. Remedy Meds is one option worth reviewing — they offer medically supervised semaglutide programs with physician oversight and pricing that is accessible for patients without insurance. You can review their program at remedymeds.co.

3. Oral GLP-1 Options

The FDA approved oral semaglutide for weight loss in December 2025. GoodRx launched a telemedicine service offering oral semaglutide starting at $149 per month for lower doses. This option eliminates injection barriers and is available at participating pharmacies across California.

4. Manufacturer Patient Assistance Programs

Novo Nordisk and Eli Lilly both operate patient assistance programs for uninsured individuals who meet income eligibility criteria. These programs can provide free or deeply discounted medication, though they require documentation and have processing timelines. Contact Novo Nordisk’s Patient Assistance Program or ask your doctor to submit a request on your behalf.

What to Do If You Are Being Forced to Stop

If you were on a GLP-1 medication through Medi-Cal and your access was cut, the most important thing is not to stop abruptly without a plan. Weight regain after stopping GLP-1 therapy is real and happens quickly. Research shows most patients return to near-baseline weight within 18 months of stopping, with regain of about 1.8 pounds per month for semaglutide users.

Talk to your physician about a transition strategy. Options include stepping down the dose gradually, switching to an oral GLP-1, or exploring telehealth programs that offer price transparency upfront.

California advocacy groups are pushing back on the Medi-Cal decision, and coverage policies could change again. The California Medical Association has called the cut medically inappropriate for patients who need GLP-1 therapy to manage a chronic disease.

The Bigger Picture

The Medi-Cal coverage cut reflects a tension running through American healthcare right now: GLP-1 drugs have overwhelming evidence behind them, yet access is still being rationed by cost. The FDA has made brand-name access easier. TrumpRx has made pricing more realistic at the retail level. But for Medicaid populations — often the highest-risk patients for obesity-related disease — coverage gaps remain a genuine equity problem.

If you are a California patient navigating this, you are not alone and you are not without options. The path to continued treatment exists; it just requires a different plan than it did six months ago.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication. Last updated: March 2026.